Vor Biopharma Inc. (VOR)

USD 0.89

(-8.84%)

Market Cap (In USD)

61.11 Million

Revenue (In USD)

-

Net Income (In USD)

-117.86 Million

Avg. Volume

871.38 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.63-3.14
PE
-
EPS
-
Beta Value
-0.408
ISIN
US9290331084
CUSIP
929033108
CIK
1817229
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Robert Ang M.B.A., M.D., MBBS
Employee Count
-
Website
https://www.vorbio.com
Ipo Date
2021-02-05
Details
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.